1. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. Issue 2 (February 2022) Authors: Cella, David; Motzer, Robert J; Suarez, Cristina; Blum, Steven I; Ejzykowicz, Flavia; Hamilton, Melissa; Wallace, Joel F; Simsek, Burcin; Zhang, Joshua; Ivanescu, Cristina; Apolo, Andrea B; Choueiri, Toni K Journal: Lancet oncology Issue: Volume 23:Issue 2(2022) Page Start: 292 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗